Ixifi
E242410
Ixifi is a biosimilar version of the monoclonal antibody infliximab, used to treat various autoimmune inflammatory conditions such as rheumatoid arthritis and Crohn’s disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ixifi canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190628 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ixifi Context triple: [Remicade, hasBiosimilar, Ixifi]
-
A.
Ixil
Ixil is a Mayan language spoken primarily by the Ixil people in the highlands of Guatemala.
-
B.
Xerus
Xerus is a genus of African ground squirrels known for their diurnal, social behavior and adaptation to open, arid habitats.
-
C.
Ifoghas
The Ifoghas are a prominent Tuareg clan from the Adrar des Ifoghas region of northeastern Mali, historically influential in Saharan trade and regional politics.
-
D.
Fakui
Fakui is the given name of Zhang Fakui, a notable Chinese military figure.
-
E.
Máfil
Máfil is a small town and commune located in southern Chile's Los Ríos Region, known for its rural character and forestry-based economy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ixifi Target entity description: Ixifi is a biosimilar version of the monoclonal antibody infliximab, used to treat various autoimmune inflammatory conditions such as rheumatoid arthritis and Crohn’s disease.
-
A.
Ixil
Ixil is a Mayan language spoken primarily by the Ixil people in the highlands of Guatemala.
-
B.
Xerus
Xerus is a genus of African ground squirrels known for their diurnal, social behavior and adaptation to open, arid habitats.
-
C.
Ifoghas
The Ifoghas are a prominent Tuareg clan from the Adrar des Ifoghas region of northeastern Mali, historically influential in Saharan trade and regional politics.
-
D.
Fakui
Fakui is the given name of Zhang Fakui, a notable Chinese military figure.
-
E.
Máfil
Máfil is a small town and commune located in southern Chile's Los Ríos Region, known for its rural character and forestry-based economy.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biologic disease-modifying antirheumatic drug
ⓘ
biosimilar medicinal product ⓘ monoclonal antibody ⓘ |
| belongsToPharmacologicalClass |
TNF-α blocking agent
ⓘ
immunosuppressant ⓘ |
| hasAbbreviation | TNF-α inhibitor ⓘ |
| hasActiveSubstance | infliximab-qbtx ⓘ |
| hasAdministrationSchedule | induction followed by maintenance dosing ⓘ |
| hasATCCode | L04AB02 ⓘ |
| hasCommonAdverseEffect |
headache
ⓘ
infusion-related reaction ⓘ upper respiratory tract infection ⓘ |
| hasContraindication |
moderate to severe heart failure
ⓘ
severe infections ⓘ |
| hasDosageForm | concentrate for solution for infusion ⓘ |
| hasImmunoglobulinType | IgG1 ⓘ |
| hasIndication |
Crohn’s disease
ⓘ
ankylosing spondylitis ⓘ pediatric Crohn’s disease ⓘ pediatric ulcerative colitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| hasLegalStatus | approved biologic medicine ⓘ |
| hasManufacturer | Pfizer ⓘ |
| hasMechanismOfAction |
binds to soluble and transmembrane TNF-α
ⓘ
inhibits TNF-α mediated inflammatory responses ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasReferenceProduct | Remicade ⓘ |
| hasRegulatoryPathway | biosimilar approval pathway ⓘ |
| hasSeriousRisk |
malignancy
ⓘ
reactivation of latent tuberculosis ⓘ serious infections ⓘ |
| hasUSApprovalYear | 2017 ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isApprovedIn |
United States of America
ⓘ
surface form:
United States
|
| isBiosimilarTo | infliximab ⓘ |
| isPrescriptionStatus | prescription only ⓘ |
| isProducedIn | recombinant cell culture ⓘ |
| isUsedFor | autoimmune inflammatory diseases ⓘ |
| isUsedInCombinationWith | methotrexate for rheumatoid arthritis ⓘ |
| requiresMonitoring |
hepatic function
ⓘ
signs and symptoms of infection ⓘ tuberculosis status ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | tumor necrosis factor alpha ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ixifi Description of subject: Ixifi is a biosimilar version of the monoclonal antibody infliximab, used to treat various autoimmune inflammatory conditions such as rheumatoid arthritis and Crohn’s disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.